A selective antagonist of mineralocorticoid receptor eplerenone in cardiology practice

被引：0
|
作者：
Gegenava, B. B. [1 ]
Drapkina, O. M. [1 ]
机构：
[1] IM Sechenov First Moscow State Med Univ, Moscow 119991, Russia
来源：
RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | 2015年 / 11卷 / 02期
关键词：
aldosterone; heart failure; atrial fibrillation; chronic renal failure; albuminuria; eplerenone; spironolactone; gynecomastia;
D O I：
10.20996/1819-6446-2015-11-2-177-181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The role of aldosterone in pathophysiological processes is considered. The effects of the selective antagonist of mineralocorticoid receptor eplerenone are analyzed. The advantages of eplerenone compared with spironolactone are discussed.
引用
收藏
页码：177 / 181
页数：5
相关论文
共 50 条
  • [31] Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males
    Krug, Alexander W.
    Stelzner, Lissy
    Rao, Ajaykumar D.
    Lichtman, Andrew H.
    Williams, Gordon H.
    Adler, Gail K.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (03): : 386 - 391
  • [32] Exciting new drugs on the horizon - Eplerenone, a selective aldosterone receptor antagonist (SARA)
    Coats, AJS
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 80 (01) : 1 - 4
  • [33] 10.13 Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients
    C. Savoia
    R. M. Touyz
    M. Volpe
    E. L. Schiffrin
    High Blood Pressure & Cardiovascular Prevention, 2007, 14 (3) : 145 - 145
  • [34] Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
    Lainscak, Mitja
    Pelliccia, Francesco
    Rosano, Giuseppe
    Vitale, Cristiana
    Schiariti, Michele
    Greco, Cesare
    Speziale, Giuseppe
    Gaudio, Carlo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 200 : 25 - 29
  • [35] The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes
    Johansen, Marie Louise
    Ibarrola, Jaime
    Fernandez-Celis, Amaya
    Schou, Morten
    Sonne, Mette Pauli
    Refsgaard Holm, Maria
    Rasmussen, Jon
    Dela, Flemming
    Jaisser, Frederic
    Faber, Jens
    Rossignol, Patrick
    Lopez-Andres, Natalia
    Kistorp, Caroline
    DIABETES, 2021, 70 (01) : 196 - 203
  • [36] The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
    Zharikov, A. Yu
    Filinova, S. O.
    Mazko, O. N.
    Makarova, O. G.
    Bobrov, I. P.
    Bryukhanov, V. M.
    BYULLETEN SIBIRSKOY MEDITSINY, 2021, 20 (02): : 29 - 35
  • [37] Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release
    Hlavacova, Natasa
    Bakos, Jan
    Jezova, Daniela
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (05) : 779 - 786
  • [38] Eplerenone, a novel and selective aldosterone receptor antagonist: Efficacy in patients with mild to moderate hypertension
    Epstein, M
    Menard, J
    Alexander, J
    Roniker, B
    CIRCULATION, 1998, 98 (17) : 98 - 99
  • [39] Eplerenone: hypertension, heart failure and the importance of mineralocorticoid receptor blockade
    Funder, John W.
    FUTURE CARDIOLOGY, 2006, 2 (05) : 535 - 541
  • [40] Placing an EMPHASIS on the mineralocorticoid receptor—benefit of eplerenone in mild HF
    Alexandra King
    Nature Reviews Cardiology, 2011, 8 (1) : 1 - 1
12345